STOCK TITAN

Rule 10b5-1 plan leads CareDx (CDNA) CEO share sales

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

CareDx, Inc. President and CEO John Walter Hanna Jr., who is also a director, reported open-market sales of the company’s common stock. On January 21, 2026, he sold 200 shares at $21.00 per share, and on January 22, 2026, he sold 19,280 shares at a weighted average price of $21.163 per share. These transactions were coded as open market sales and were made under a Rule 10b5-1 trading plan adopted on December 13, 2024. Following the later transaction, he beneficially owned 597,405 shares of CareDx common stock directly.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hanna John Walter JR

(Last) (First) (Middle)
C/O CAREDX, INC.
8000 MARINA BOULEVARD, 4TH FLOOR

(Street)
BRISBANE CA 94005

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/21/2026 S(1) 200 D $21 616,685 D
Common Stock 01/22/2026 S(1) 19,280 D $21.163(2) 597,405 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.43 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ John Walter Hanna, Jr. 01/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did CareDx (CDNA) report in this Form 4?

The filing shows President and CEO John Walter Hanna Jr., also a director, sold shares of CareDx common stock in two open-market transactions and reported his updated direct holdings.

How many CareDx (CDNA) shares did the CEO sell and at what prices?

On January 21, 2026, he sold 200 shares at $21.00 per share. On January 22, 2026, he sold 19,280 shares at a weighted average price of $21.163 per share.

How many CareDx (CDNA) shares does the CEO hold after these transactions?

After the reported transactions, John Walter Hanna Jr. beneficially owned 597,405 shares of CareDx common stock directly.

Were the CareDx CEO’s share sales under a Rule 10b5-1 plan?

Yes. The filing states that the sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2024.

Why is the $21.163 price for CareDx (CDNA) shares described as a weighted average?

The filing explains that the $21.163 figure is a weighted average price for shares sold in multiple transactions at prices ranging from $21.00 to $21.43 per share, inclusive.

Does the CareDx CEO offer more detail on the individual trade prices?

The reporting person states they will provide to the issuer, any security holder, or SEC staff, upon request, full information on the number of shares sold at each separate price within the quoted range.

Caredx

NASDAQ:CDNA

CDNA Rankings

CDNA Latest News

CDNA Latest SEC Filings

CDNA Stock Data

1.08B
49.47M
3.43%
101.7%
12.97%
Diagnostics & Research
Services-medical Laboratories
Link
United States
BRISBANE